Author:
Boone N. W.,Liu L.,Romberg-Camps M. J.,Duijsens L.,Houwen C.,van der Kuy P. H. M.,Janknegt R.,Peeters R.,Landewé R. B. M.,Winkens B.,van Bodegraven A. A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference20 articles.
1. European Medicines Agency (EMA). Guideline on similar biological medicinal products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf (accessed 14 November 2017)
2. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim MJ, Lee YA, Lee SJ, Kim HU, Yoo DH, Braun J (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and effectiveness of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72(10):1605–1612. https://doi.org/10.1136/annrheumdis-2012-203091
3. Jørgensen KK, Olsen IC, Goll GL et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389(10086):2304–2316. https://doi.org/10.1016/S0140-6736(17)30068-5
4. Ordas I, Feagan BG, Sandborn WJ (2012) Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10(10):1079–1087. https://doi.org/10.1016/j.cgh.2012.06.032
5. Handleiding behandeling IBD 2014-2015. Nederlandse Vereniging van Maag-, Darm- en leverartsen, oktober 2015. Available at: https://www.icc-ibd.com/upload/files/DocumentvolledigHandleidingmetliteratuurvs7.21.pdf . Accessed 19 Jan 2018
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献